Anti-Human IL-4Rα (CD124) (Dupilumab) – Fc Muted™

Anti-Human IL-4Rα (CD124) (Dupilumab) – Fc Muted™

Product No.: I-1265

- -
- -
Product No.I-1265
Clone
REGN668
Target
IL-4Rα
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
IL-4R-alpha, CD124, IL4R
Isotype
Human IgG4κ
Applications
B
,
ELISA
,
FA

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Muted
Immunogen
Unknown
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
B,
ELISA,
FA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Dupilumab. REGN668 (Dupilumab) is an antagonist of human IL-4Rα, the α subunit of the IL-4 receptor.
Background
IL-4R is a heterodimeric receptor composed of a common subunit (IL-4Rα) that pairs with distinct auxiliary subunits1 to create Type I and Type II IL-4 receptors as well as the IL-13 receptor system2. The IL-4/IL-13/IL-4R axis promotes T helper 2 (Th2) cell differentiation and mediates the pro-allergic adaptive immune response1. The IL‐4R pathway is central to allergic inflammation via its ligands IL-4 and IL-131, driving disease progression in atopic and allergic diseases3. IL‐4R activates effector pathways in target tissues where disease occurs1. Immunotherapies targeting IL-4R are being sought to interrupt the allergic inflammatory response.

REGN668 (Dupilumab) selectively binds to IL-4Rα and inhibits the signaling of type 2 (Th2) cytokines IL-4 and IL-13, thereby inhibiting the release of proinflammatory cytokines, chemokines, and IgE as well as reducing key Th2-associated biomarkers3. An increase in serum levels of IL-4 and IL-13 is seen following blockade. Additionally, dupilumab inhibits IgE production by ex vivo B cells induced by IL-4 treatment 1. Since IL-4Rα is targeted, dupilumab can block both Type I and Type II receptors. However, based on clinical data, dupilumab may not equally inhibit both receptor types1. IL-4 signaling is inhibited via the Type I receptor. While both IL-4 and IL13 signaling are inhibited via the Type II receptor.

Dupilumab has been approved for the treatment of atopic dermatitis and eosinophilic asthma.
Antigen Distribution
Type I IL-4R is composed of IL-4Rα and the γc chain and is expressed on hematopoietic cells. Type II IL-4R is composed of IL-4Rα and IL-13Rα1 and is expressed on both hematopoietic and non-hematopoietic cells, such as airway epithelium.
Ligand/Receptor
IL-4, IL-13
NCBI Gene Bank ID
UniProt.org
Research Area
Apoptosis
.
Cell Biology
.
Cell Death
.
Immunology
.
Inflammatory Disease
.
Signal Transduction
.
Transcription Factors
.
Tumor Suppressors
.
Pro-Inflammatory Cytokines

References & Citations

1. Harb H, Chatila TA. Clin Exp Allergy. 50(1):5-14. 2020.
2. Kovalenko P, DiCioccio AT, Davis JD, et al. CPT Pharmacometrics Syst Pharmacol. 5(11):617-624. 2016.
3. Shirley M. Drugs. 77(10):1115-1121. 2017.
4. Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. J Allergy Clin Immunol. 134(6):1293-1300. 2014.
5. Jonstam K, Swanson BN, Mannent LP, et al. Allergy. 74(4):743-752. doi: 2019.
6. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Lancet. 389(10086):2287-2303. 2017.
7. Rabe KF, Nair P, Brusselle G, et al. N Engl J Med. 378(26):2475-2485. 2018.
8. Wollenberg A, Beck LA, Blauvelt A, et al. Br J Dermatol. 182(5):1120-1135. 2020.
B
Indirect Elisa Protocol
FA

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.